FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 702 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR 27-Year-Old Diagnosed with Cancer at 20 Weeks Pregnant Gives Birth Amid... July 3, 2020 Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint... February 21, 2024 Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... November 10, 2023 Study Shows CAR T-Cell Therapy Is Effective at Putting Childhood Leukemia... December 12, 2022 Load more HOT NEWS HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... 2026 Heine H. Hansen Award Recipient Announced COVID-19: “We’ve got so much on our plates” Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors...
